Teprotumumab Anti-insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody Treatment of thyroid eye disease

被引：0

作者：

Desideri, L. Ferro ^{[1
]}

Vagge, A. ^{[1
,2
]}

del Noce, C. ^{[1
,2
]}

Nicolo, M. ^{[1
,2
,3
]}

Traverso, C. E. ^{[1
,2
]}

机构：

[1] Osped Policlin San Martino, IRCCS, Univ Eye Clin Genoa, Genoa, Italy

[2] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy

[3] Macula Onlus Fdn, Genoa, Italy

来源：

DRUGS OF THE FUTURE | 2020年 / 45卷 / 01期

关键词：

Thyroid-associated ophthalmopathy; Thyroid eye disease; Graves' disease; RV-001; Teprotumumab; IGF-1R; GRAVES-DISEASE; RECEPTOR; TSH; PATHOGENESIS; STIMULATION; GROWTH; CELLS;

D O I：

10.1358/dof.2020.45.1.3117466

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease, is the most common ocular manifestation in patients with Graves' disease. High-dose glucocorticoids and other immunosuppressive agents represent the most adopted treatment options for TAO; however, none of them has given optimal results in terms of clinical efficacy and safety. Teprotumumab is a novel, fully human insulin-like growth factor 1 receptor (IGF-1R) inhibitory monoclonal antibody developed for the management of TAO. A phase trial of teprotumumab showed promising results in terms of clinical efficacy and safety for treating TAO, and supported the drug's approval in the U.S. in January 2020, making it the first drug approved for this disease. In this review, we discuss teprotumumab's pharmacodynamics and its clinical efficacy, focusing also on its safety and tolerability profile.

引用

页码：21 / 25

页数：5

共 27 条

[1] Management of Graves Disease A Review [J].

Burch, Henry B. ;

Cooper, David S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (23) :2544-2554

[2] Anti-VEGF Therapy for Retinal Vein Occlusions [J].

Campa, Claudio ;

Alivernini, Giuseppe ;

Bolletta, Elena ;

Parodi, Maurizio Battaglia ;

Perri, Paolo .

CURRENT DRUG TARGETS, 2016, 17 (03) :328-336

[3] Teprotumumab, an IGF-1R Blocking Monoclonal Antibody Inhibits TSH and IGF-1 Action in Fibrocytes [J].

Chen, Hong ;

Mester, Tuende ;

Raychaudhuri, Nupur ;

Kauh, Courtney Y. ;

Gupta, Shivani ;

Smith, Terry J. ;

Douglas, Raymond S. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (09) :E1635-E1640

[4] Role of SFP1 in the Regulation of Candida albicans Biofilm Formation [J].

Chen, Hsueh-Fen ;

Lan, Chung-Yu .

PLOS ONE, 2015, 10 (06)

[5] Treatment of adult Graves' disease [J].

Corvilain, Bernard ;

Hamy, Antoine ;

Brunaud, Laurent ;

Borson-Chazot, Francoise ;

Orgiazzi, Jacques ;

Hachmi, Leila Bensalem ;

Semrouni, Mourad ;

Rodien, Patrice ;

Lussey-Lepoutre, Charlotte .

ANNALES D ENDOCRINOLOGIE, 2018, 79 (06) :618-635

[6] Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration [J].

Desideri, Lorenzo Ferro ;

Barra, Fabio ;

Ferrero, Simone ;

Traverso, Carlo Enrico ;

Nicolo, Massimo .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (08) :735-751

[7] Methodological concerns on retinal and choroidal thickness variations measured by optical coherence tomography in patients with epilepsy [J].

Desideri, Lorenzo Ferro ;

Barra, Fabio ;

Ferrero, Simone .

EPILEPSY & BEHAVIOR, 2019, 94 :312-312

[8] Systemic and intraocular factors related to retinal thicknesses variations in patients with Parkinson's disease [J].

Desideri, Lorenzo Ferro ;

Barra, Fabio ;

Ferrero, Simone .

PARKINSONISM & RELATED DISORDERS, 2019, 61 :234-235

[9] Teprotumumab for the Treatment of Active Thyroid Eye Disease [J].

Douglas, R. S. ;

Kahaly, G. J. ;

Patel, A. ;

Sile, S. ;

Thompson, E. H. Z. ;

Perdok, R. ;

Fleming, J. C. ;

Fowler, B. T. ;

Marcocci, C. ;

Marino, M. ;

Antonelli, A. ;

Dailey, R. ;

Harris, G. J. ;

Eckstein, A. ;

Schiffman, J. ;

Tang, R. ;

Nelson, C. ;

Salvi, M. ;

Wester, S. ;

Sherman, J. W. ;

Vescio, T. ;

Holt, R. J. ;

Smith, T. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (04) :341-352

[10] B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: Implications for disease pathogenesis [J].

Douglas, Raymond S. ;

Naik, Vibharavi ;

Hwang, Catherine J. ;

Afifiyan, Nikoo F. ;

Gianoukakis, Andrew G. ;

Sand, Daniel ;

Kamat, Shweta ;

Smith, Terry J. .

JOURNAL OF IMMUNOLOGY, 2008, 181 (08) :5768-5774

← 1 2 3 →